Pharmacovigilance in Europe: the European Commission’s proposals endanger the population
A series of public health disasters (from thalidomide in the 1960s to rofecoxib (Vioxx°) at the beginning of this century) have served to remind us of the crucial nature of pharmacovigilance. To this end, the European Commission’s proposed legislative changes represent a serious regression in the protection of European citizens.
Health Action International (HAI) Europe, International Society of Drug Bulletins (ISDB) and Medicine in Europe Forum (MiEF) find that “EMEA’s draft transparency policy” fails to restore citizens’ trust in its decision-making.
Trasparency should be the norm
read (255 KB)